Mazaticol
Chemical compound
- N04AA10 (WHO)
- In general: uncontrolled
- [(1R,3R,5R)-6,6,9-trimethyl-9-azabicyclo[3.3.1]non-3-yl hydroxy(di-2-thienyl)acetate
- 42024-98-6
- 68667
- 61921
- I6X824OGWZ
- DTXSID1057743
- Interactive image
- CC1(CC[C@@H]2C[C@H](C[C@H]1N2C)OC(=O)C(c3cccs3)(c4cccs4)O)C
InChI
- InChI=1S/C21H27NO3S2/c1-20(2)9-8-14-12-15(13-16(20)22(14)3)25-19(23)21(24,17-6-4-10-26-17)18-7-5-11-27-18/h4-7,10-11,14-16,24H,8-9,12-13H2,1-3H3/t14-,15-,16-/m1/s1
- Key:AMHPTVWBZSYFSS-BZUAXINKSA-N
Mazaticol (Pentona) is an anticholinergic used as an antiparkinsonian agent in Japan.
The compound was known as PG-501 is first mentioned in Japanese studies in the early 1970s, noting "PG-501 was found to have pronounced anti-acetylcholine, anti-tremorine-induced tremor, anti-physostigmine-induced death, anti-haloperidol-induced parkinsonism and anti EEG arousal activities."[1][2]
References
- ^ Nose T, Kojima M, Ishida R, Shintomi K, Kowa Y (July 1971). "[Pharmacological properties of 6,6,9-trimethyl-9-azabicyclo (3,3,1)non-3 beta-yl-alpha, alpha-di(2-thienyl) glycolate hydrochloride monohydrate (PG-501), a new anti-parkinsonian agent]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica (in Japanese). 67 (4): 387–405. doi:10.1254/fpj.67.387. PMID 5000167.
- ^ Kosaka K (1971). "パ ー キ ン ソ ン病 に対 す るPG-501の 使 用 経 験/The Beneficial Effect of PG-501 on Parkinsonism". Rinsho Yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 2 (3): 230–235. doi:10.3999/jscpt.2.230. Retrieved December 18, 2023.
External links
- Government registered description of mazaticol (Pentona) (Japanese)[permanent dead link]
- v
- t
- e
Antiparkinson agents (N04)
DA precursors |
|
---|---|
DA receptor agonists |
|
MAO-B inhibitors | |
COMT inhibitors | |
AAAD inhibitors |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e